NorthRock Partners Boosts Eli Lilly Stake by 6.5%

The investment firm added 942 shares of the pharmaceutical giant in Q3 2025.

Mar. 14, 2026 at 12:37pm

Got story updates? Submit your updates here. ›

NorthRock Partners LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 6.5% during the third quarter, according to a recent SEC filing. The fund now owns 15,361 shares of the company's stock, valued at $11.72 million.

Why it matters

Eli Lilly is one of the world's largest pharmaceutical companies, known for developing innovative drugs across a range of therapeutic areas. Institutional investors closely monitor changes in ownership of Lilly's stock, as it can signal confidence or concerns about the company's future performance.

The details

NorthRock Partners, an investment management firm, added 942 shares of Eli Lilly to its portfolio in Q3 2025. This increased the firm's total holdings in Lilly to 15,361 shares. The purchase was part of NorthRock's broader strategy to invest in major pharmaceutical companies with strong product pipelines and market positions.

  • NorthRock Partners increased its Eli Lilly stake during the third quarter of 2025.

The players

NorthRock Partners LLC

An investment management firm that raised its stake in Eli Lilly and Company.

Eli Lilly and Company

A global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana, known for developing innovative drugs across a range of therapeutic areas.

Got photos? Submit your photos here. ›

The takeaway

NorthRock Partners' increased investment in Eli Lilly reflects ongoing institutional confidence in the pharmaceutical company's growth prospects, driven by its robust product pipeline and market leadership position.